ArticleBreast cancer (Tokyo, Japan)2026
Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study.
Xiaoyi Zhang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.